BACKGROUND: VDD pacemakers may be implanted in the setting of atrioventricular block with preserved sinus function. Their main advantage over DDD pacemakers is use of a single lead. However, low-amplitude atrial electrograms (EGMs) recorded from the free-floating atrial electrode may lead to undersensing. There is currently no way of predicting EGM amplitude prior to implantation and to thus identify candidates who may be safely implanted with a VDD pacemaker. AIM: We sought to investigate whether the P-wave amplitude measured on the standard surface ECG correlates with the atrial EGM amplitude measured by the single-pass lead at implantation. METHODS: Data on 122 patients implanted with a VDD pacemaker at our institution were reviewed. Atrial EGM amplitudes measured at implantation by the single-pass lead were correlated with the maximal P-wave amplitude on the surface ECG recorded just prior to implantation. RESULTS: There was a highly significant correlation between the maximal P-wave amplitude on the surface ECG and the atrial EGM (Pearson's correlation 0.313, P<0.001). Multivariate analysis showed that maximal P-wave amplitude was independently associated with atrial EGM amplitude (p=0.003). For the overall population, an EGM amplitude of <0.9 mV was present in only 11/122 (9%) cases. An atrial EGM amplitude of <0.9 mV was found in 10/69 (14%) of patients with a maximal surface P-wave < or =0.1 mV but only in 1/53 (2%) of those with >0.1 mV (p=0.023). CONCLUSION: Low-amplitude atrial EGMs at implantation are found in a minority of patients with single-pass leads. However, patients with a maximal surface P-wave amplitude of >0.1 mV are especially unlikely to have a low atrial EGM amplitude and may be good candidates for a VDD pacemaker.
BACKGROUND: VDD pacemakers may be implanted in the setting of atrioventricular block with preserved sinus function. Their main advantage over DDD pacemakers is use of a single lead. However, low-amplitude atrial electrograms (EGMs) recorded from the free-floating atrial electrode may lead to undersensing. There is currently no way of predicting EGM amplitude prior to implantation and to thus identify candidates who may be safely implanted with a VDD pacemaker. AIM: We sought to investigate whether the P-wave amplitude measured on the standard surface ECG correlates with the atrial EGM amplitude measured by the single-pass lead at implantation. METHODS: Data on 122 patients implanted with a VDD pacemaker at our institution were reviewed. Atrial EGM amplitudes measured at implantation by the single-pass lead were correlated with the maximal P-wave amplitude on the surface ECG recorded just prior to implantation. RESULTS: There was a highly significant correlation between the maximal P-wave amplitude on the surface ECG and the atrial EGM (Pearson's correlation 0.313, P<0.001). Multivariate analysis showed that maximal P-wave amplitude was independently associated with atrial EGM amplitude (p=0.003). For the overall population, an EGM amplitude of <0.9 mV was present in only 11/122 (9%) cases. An atrial EGM amplitude of <0.9 mV was found in 10/69 (14%) of patients with a maximal surface P-wave < or =0.1 mV but only in 1/53 (2%) of those with >0.1 mV (p=0.023). CONCLUSION: Low-amplitude atrial EGMs at implantation are found in a minority of patients with single-pass leads. However, patients with a maximal surface P-wave amplitude of >0.1 mV are especially unlikely to have a low atrial EGM amplitude and may be good candidates for a VDD pacemaker.